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ABSTRACT: Denervation of oropharyngeal muscles in ob-
structive sleep apnea (OSA) has been suggested by needle
electromyography (EMG) and muscle biopsy, but little is known
about oropharyngeal nerve conduction abnormalities in OSA.
We sought to compare hypoglossal nerve conduction studies in
patients with and without OSA. Unilateral hypoglossal nerve
conduction studies were performed on 20 subjects with OSA
and 20 age-matched controls using standard techniques. Me-
dian age was 48 years in OSA subjects and 47 years in con-
trols. Hypoglossal compound muscle action potential (CMAP)
amplitudes were significantly reduced (P ¼ 0.01, Wilcoxon
signed-rank test), but prolongation of latencies in OSA subjects
did not reach significance in comparison to those of controls.
Among a subgroup of subjects without polyneuropathy (15
pairs), reduced amplitudes in OSA subjects retained borderline
significance (P ¼ 0.05). Hypoglossal nerve conduction abnor-
malities may distinguish patients with OSA from controls. These
abnormalities could potentially contribute to, or arise from,
OSA.
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Obstructive sleep apnea (OSA) is a common sleep
disorder that affects approximately 2–4% of
adults.1 OSA is a major public health issue because
of its association with automobile accidents,
decreased quality of life, and cardiac and cerebro-
vascular events.2 Although OSA appears to result
from intermittent airway occlusion during sleep,
the pathophysiology of OSA is not completely
understood. The genioglossus, an extrinsic muscle
of the tongue innervated by the hypoglossal nerve,
is considered one of the most important oropha-
ryngeal dilators to maintain airway patency. Histo-
logical changes in the genioglossus of OSA
patients suggest neuromuscular impairment of this
muscle as a possible consequence or concomitant
of OSA.3
Needle electromyography (EMG) of oropharyn-
geal muscles in OSA has demonstrated focal par-
tial denervation,4 a finding confirmed by micro-
scopic evaluation of palatal tissue.4,5 However, the
significance of oropharyngeal muscle denervation
or any type of neuromuscular dysfunction of the
oropharynx in OSA is controversial.6,7 Neuromus-
cular dysfunction of the oropharynx may be part
of the pathophysiology of OSA, or it may be a con-
sequence of repeated episodes of hypoxemia or
snoring related to OSA. Investigation of the role of
neuromuscular dysfunction in OSA patients is chal-
lenging, as needle EMG of the oropharynx is pain-
ful and tissue biopsies are invasive. To improve
understanding of neuromuscular dysfunction in
OSA, we sought to investigate non-invasive nerve
conduction studies (NCS) of the oropharynx. Spe-
cifically, the purpose of this study was to investigate
hypoglossal NCS in patients with OSA and age-
matched controls.
METHODS
Subjects. OSA Subjects. Twenty OSA patients,
aged 18–60 years, with an apnea–hypopnea index
(AHI) 20 based on full polysomnography, were
identified from the University of Michigan Sleep
Laboratory or the outpatient Sleep Disorders
Clinic. Exclusion criteria included previous signifi-
cant facial trauma that caused fracture or facial de-
formity, head or neck cancer, previous face or
neck surgery (including tonsillectomy or adenoid-
ectomy), previous radiation therapy to head or
neck, known diagnosis of peripheral neuropathy,
any implanted device (nerve stimulator, implanted
pump, pacemaker, defibrillator), and known
pregnancy.
Control Subjects. Twenty patients without a gen-
eralized neuromuscular (neuropathy, myopathy, or
neuromuscular junction) disorder were identified
from the University of Michigan EMG laboratory
after performing an EMG study for clinical pur-
poses. The aforementioned exclusion criteria for
OSA subjects were also applied for controls. The
Berlin questionnaire was used to exclude those
with a high risk of sleep apnea.8 Control subjects
were initially individually matched on age 65
years; this was later expanded to 67 years.
Abbreviations: AHI, apnea–hypopnea index; BMI, body mass index;
CMAP, compound muscle action potential; CPAP, continuous positive air-
way pressure; EMG, needle electromyography IQR, interquartile range;
NCS, nerve conduction studies; OSA, obstructive sleep apnea
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Study Procedures. Reports of diagnostic polysom-
nograms performed in a sleep laboratory accred-
ited by the American Academy of Sleep Medicine
were used to determine initial sleep apnea severity
for each OSA subject. Studies had been recorded
following standard techniques, and they were
scored by technologists using previously described
quality-control methods and published scoring cri-
teria,9 similar to those recommended for clinical
research and clinical studies.10,11 Obstructive sleep
apnea for this study was defined by an AHI 20
with obstructive apneas plus hypopneas exceeding
the number of central apneas. This non-standard
AHI threshold was selected to maximize the chan-
ces of finding a difference between OSA and con-
trol subjects by eliminating those with less severe
disease. Medical records were reviewed, and a his-
tory of diabetes was abstracted, supplemented by
patient report. Height and weight were self-
reported. The speech of each subject was assessed
during the encounter by an EMG technologist,
and presence of dysarthria was noted. The electro-
physiological studies were performed by a regis-
tered EMG technologist or a board-certified neu-
rologist with fellowship training in EMG.
Cranial Nerve Testing. A right hypoglossal (cra-
nial nerve 12) NCS was performed on all subjects
using a standard published technique (Fig. 1).12
Both a recording and a reference electrode, posi-
tioned 2 cm apart on a tongue blade, were placed
on the dorsal surface of the hemi-tongue, over
intrinsic tongue muscles. A ground electrode was
placed on the cheek. Bipolar percutaneous stimu-
lation using a 0.02-ms duration, 100-mA electrical
stimulus was applied along the base of the mandi-
ble, with pressure applied to the stimulator.12,13
The duration of the electrical stimulus was gradu-
ally increased until a supramaximal compound
muscle action potential (CMAP) waveform was
achieved.
Limb Testing. Control subjects were recruited
from patients who had nerve conduction studies
performed as clinically indicated for mononeuro-
pathies (n ¼ 8); unilateral upper extremity numb-
ness, pain, or weakness (n ¼ 5); unilateral lower
extremity numbness, pain, or weakness (n ¼ 1);
bilateral upper extremity symptoms (n ¼ 1); bilat-
eral lower extremity symptoms (n ¼ 4); or four ex-
tremity distal numbness or burning (n ¼ 1).
Twelve control subjects had only upper extremity
NCS, but no symptoms or examination findings to
suggest lower extremity abnormalities. Seven of the
controls had abnormal EMGs, including unilateral
median neuropathy at the wrist (n ¼ 3), ulnar neu-
ropathy at the elbow (n ¼ 2), lateral antebrachial
cutaneous mononeuropathy (n ¼ 1), and tibial
neuropathy (n ¼ 1). The OSA subjects had limb
NCS performed in accordance with the following
protocol: sural sensory and peroneal motor NCS
were performed in the right leg. If both studies
were normal, no further NCS were performed.
Otherwise, additional NCS were performed in ac-
cordance with established research NCS stand-
ards.14 Lower limb surface temperatures were
maintained above 32C. Polyneuropathy was
defined as electrodiagnostic evidence of an abnor-
mal amplitude or latency of the sural sensory NCS
and one other separate nerve.14
Statistical Methods. Baseline characteristics were
calculated using frequencies and percents, or
medians and interquartile ranges (IQRs), and were
compared between OSA subjects and controls
using the Wilcoxon rank-sum tests or Fisher’s exact
tests. The percentage of abnormal hypoglossal
NCS values was calculated based on published nor-
mal values. Values were designated as abnormal if
they were not within this 95% confidence interval
(CI).13 The Wilcoxon signed-rank test was used to
compare hypoglossal nerve amplitudes and laten-
cies between OSA and control subjects. These anal-
yses were repeated to exclude pairs where the OSA
subject had NCS results consistent with polyneu-
ropathy. To test the discriminatory ability of the
hypoglossal amplitude value in separating OSA
from control subjects, we calculated the c-statistic.
Statistical analyses were performed using S-Plus
(version 7.0) for Windows and SAS (version 9.1)
for Windows. The project was approved by the
institutional review board of the University of
Michigan. Written informed consent was obtained
from each subject.
RESULTS
Baseline characteristics of the 20 OSA subjects and
20 age-matched controls are reported in Table 1.
The median AHI on diagnostic polysomnograms
for patients with OSA was 47 (range 28–68); the
median minimum oxygen saturation was 88% (85–
90). Only 3 (15%) OSA subjects were not using
positive airway pressure therapy. Five (25%) of the
OSA subjects were found to have polyneuropathy
using NCS criteria. None of the controls hadFIGURE 1. Hypoglossal nerve conduction testing.
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evidence of polyneuropathy, as dictated by the
exclusion criteria. Of the 9 control subjects who
had sural NCS performed, none had an abnormal
latency or amplitude. Sural nerve testing, in both
the entire group and the 15 pairs without polyneu-
ropathy, showed conflicting results: the amplitudes
were lower in the OSA group and the latencies
were longer in the control group (Tables 2 and 3).
No subject had dysarthria.
Compared with published normal values, 13
(65%) of the OSA subjects had an abnormal hypo-
glossal CMAP amplitude, and 10 (50%) had an
abnormal latency. In contrast, 3 (15%) of the con-
trol subjects had an abnormal hypoglossal ampli-
tude, and 4 (20%) had an abnormal latency.
Amplitudes were significantly reduced, but prolon-
gation of latencies did not show significant differ-
ences between OSA subjects and controls (Table
2). The c-statistic for hypoglossal amplitude was
0.81. This suggests good discrimination between
OSA and control subjects. Among the 15 pairs of
subjects without polyneuropathy, the reduced
amplitudes in OSA subjects were borderline signifi-
cant (Table 3).
DISCUSSION
This prospective study of 20 OSA patients and 20
individually age-matched control subjects shows
that OSA patients have NCS findings suggestive of
a hypoglossal mononeuropathy compared with
controls, and that this difference cannot be attrib-
uted to a generalized polyneuropathy. If OSA
causes hypoglossal mononeuropathy, the possible
etiologies include mechanical forces (vibration
from snoring) and hypoxic or ischemic injury.
Clinical and animal studies have shown that vibra-
tion has the capacity to cause snoring-induced
focal demyelination more than axonal injury.15
However, it remains unclear whether vibration dur-
ing snoring is sufficient to produce hypoglossal
nerve injury. Nerve ischemia generally affects large
myelinated axons, which reduces CMAP amplitude
and slows distal nerve conduction. However, we
cannot explain how ischemia might affect the
hypoglossal nerve and not peripheral nerves more
generally. To our knowledge, relative ischemic
thresholds of hypoglossal nerves, as compared with
other nerves, have not been studied.
Our findings are complemented by a recent
needle EMG study16 that found increased duration
and area of genioglossus motor unit action poten-
tials in OSA patients. This finding is consistent
with prior denervation and subsequent reinnerva-
tion due to axonal loss. The electrodiagnostic evi-
dence of neurogenic findings in two separate
muscles innervated by the hypoglossal nerve, the
genioglossus and intrinsic tongue muscles, suggests
localization of dysfunction to the nerve rather than
muscle tissue. Although we did not directly assess
for primary muscle pathology, our findings are
Table 1. Baseline characteristics, expressed as median (interquartile range) or number (%).
OSA (n ¼ 20) Control (n ¼ 20) P-value
Age 48 (39–52) 47 (42–52) 0.85
Male 15 (75%) 11 (55%) 0.32
Height (inches) 70 (66–72) 68 (65–71) 0.49
Weight (pounds) 233 (209–276) 187 (170–215) 0.0027
Body mass index 32 (30–41) 28 (26–30) 0.0019
Diabetes 4 (20%) 0 (0%) 0.11
Hypertension 10 (50%) 6 (30%) 0.14
Ischemic stroke 1 (5%) 1 (5%) 1.00
OSA, obstructive sleep apnea.
Table 2. Comparison of nerve conduction results between OSA (n ¼ 20) and control (n ¼ 20) subjects.
OSA median (IQR) Control median (IQR) P-value
Hypoglossal nerve amplitude (mV) 2.35 (1.60–3.38) 4.45 (3.45–5.43) 0.01
Hypoglossal nerve distal latency (ms) 2.75 (2.20–2.93) 2.38 (2.04–2.66) 0.10
Sural peak latency* 3.3 (3.1–3.6) 3.7 (3.7–3.9)† 0.01
Sural amplitude* 8.6 (6.3–14.3) 20.6 (14.8–24.2)† 0.002
Sural NCV* 47.5 (41.0–53.8) 48.3 (43.8–48.3)† 0.9
Peroneal distal latency* 4.7 (4.2–5.2) 4.3 (4.0–4.9)† 0.4
Peroneal amplitude* 4.9 (2.8–7.6) 5.2 (4.0–9.4)† 0.3
Peroneal NCV* 43.5 (40.0–46.3) 47.0 (45.9–49.3)† 0.03
*When the nerve conduction was not recordable, a score of zero was assumed.
†Measurements from controls were done on a limited sample: sural (n ¼ 9) or peroneal (n ¼ 8).
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consistent with a hypoglossal neuropathy, which
could explain some of the pathological muscle
findings others have identified in OSA.17
Oropharyngeal muscle histopathology in OSA
patients has been attributed at times to a myopa-
thy6,7,18,19 postulated to result from ‘‘activity-
induced injury.’’19 Other investigators, however,
have interpreted the pathological changes to be of
unclear etiology, or ascribed them to both neuro-
genic and myopathic causes.20,21 Some recent his-
topathological investigations of uvulopalatophar-
yngoplasty samples clearly demonstrated muscle
fiber type grouping, grouped atrophy, and angu-
lated atrophic fibers consistent with denervation
and reinnervation from axonal loss without histo-
pathological evidence of a primary myopathy.22
Genioglossus biopsies have demonstrated increased
type II muscle fibers in OSA patients compared
with controls,17 another finding consistent with
motor nerve partial denervation that is notably
absent in OSA patients treated with chronic con-
tinuous positive airway pressure (CPAP).3 As pe-
ripheral nerve denervation and reinnervation can
result in loss of muscle force and power,23 loss of
hypoglossal axons to oropharyngeal muscles could
increase susceptibility to airway collapse. This sug-
gests that hypoglossal nerve dysfunction may pro-
mote OSA. The genioglossus is an important pha-
ryngeal dilator, and decreases in genioglossal
activity during sleep are greater in OSA patients
than controls.24 Furthermore, stimulation of the
hypoglossal nerve may relieve upper airway obstruc-
tion in OSA.25,26 These observations combine to sup-
port the hypothesis that chronic hypoglossal nerve
dysfunction could increase susceptibility to airway
collapse during sleep. Thus, a bidirectional relation-
ship may exist where OSA may result in hypoglossal
dysfunction, which may in turn worsen OSA.
Peripheral neuropathy, and more specifically
an axonal pattern of sensory nerve dysfunction,
has been identified in OSA.27–29 Treatment with
CPAP may improve this peripheral neuropathy,29
which suggests that OSA may be causally related to
a sensory peripheral neuropathy. However, when
we excluded subjects with electrodiagnostic evi-
dence of a generalized peripheral neuropathy,
hypoglossal nerve dysfunction was still apparent in
those with OSA. Therefore, the hypoglossal nerve
abnormalities that we identified in OSA subjects
seem unlikely to result from a widespread large-
fiber neuropathic process. The limb NCS results
interestingly showed lower sural amplitudes in the
OSA subjects and longer latencies in the controls,
which is difficult to reconcile. However, these dif-
ferences are not likely to be clinically significant
given that the interquartile ranges did not cross
the normal value threshold.30 We therefore postu-
late that the differences resulted from chance.
Among the limitations of our study, sleep
apnea in the control subjects was excluded based
on a validated questionnaire rather than the ‘‘gold
standard’’ of polysomnography. However, inadver-
tent inclusion of some subjects with OSA in the
control group would have decreased our ability to
identify a difference in hypoglossal NCS. Further-
more, it is possible that the abnormal hypoglossal
NCS seen in some controls were due to undiag-
nosed sleep apnea. Similarly, if CPAP use eventu-
ally improves hypoglossal nerve dysfunction, the
use of CPAP in most of our OSA subjects would
also have reduced rather than enhanced differen-
ces between groups. The presence of diabetes was
recorded based on known history; patients were
not screened for diabetes or pre-diabetes. Because
no brain imaging was performed, we do not have
information on white-matter hyperintensities or
lacunar disease, which may be associated with dia-
betes, hypertension, and OSA. We also do not
have information on possible brainstem abnormal-
ities. However, as all subjects had at least screening
NCS, subclinical large-fiber diabetic neuropathy
should have been identified.14 Control subjects
who did not have lower extremity NCS could have
had mild subclinical polyneuropathy; however, this
Table 3. Comparison of nerve conduction results between OSA patients without polyneuropathy (n ¼ 15)
and their age-matched control subjects (n ¼ 15).
OSA median (IQR) Control median (IQR) P-value
Hypoglossal nerve amplitude (mV) 2.40 (1.95–3.15) 4.10 (3.45–5.25) 0.05
Hypoglossal nerve distal latency (ms) 2.60 (2.20–2.90) 2.15 (2.00–2.58) 0.15
Sural peak latency* 3.30 (3.25–3.60) 3.75 (3.63–3.88)† 0.03
Sural amplitude* 13.50 (8.10–15.00) 21.30 (12.65–28.83)† 0.05
Sural NCV* 50.00 (46.70–53.80) 47.50 (44.52–48.30)† 0.29
Peroneal distal latency* 4.50 (4.15–5.05) 4.10 (4.00–4.80)† 0.33
Peroneal amplitude* 7.00 (3.10–7.70) 4.25 (3.85–8.10)† 0.97
Peroneal NCV* 44.00 (41.55–47.75) 46.75 (45.82–51.05)† 0.20
*When the nerve conduction was not recordable, a score of zero was assumed.
†Measurements from controls were done on a limited sample (n ¼ 6).
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could only have decreased the differences between
groups.
There was a small but significant difference in
body mass index (BMI) between the OSA and con-
trol groups. Although BMI has been shown to be
associated with small reductions in amplitude and
slightly faster velocities in sensory and mixed
nerves, a consistent relationship between BMI and
motor amplitudes or latencies has not been identi-
fied.31,32 Even the microvolt differences in sensory
and mixed nerve amplitudes related to BMI31 are
not taken into account in clinical EMG interpreta-
tion. Furthermore, although fat in the tongue
increases with increasing BMI in the posterior
tongue, BMI is not known to correlate with fat in
the intrinsic tongue muscles, the region of the
tongue with the lowest fat content.33 Taken to-
gether, this information argues against BMI as a
confounder in the current study.
This study has provided new evidence of oro-
pharyngeal nerve dysfunction in OSA by means of
a non-invasive technique. However, our data can-
not definitively determine whether hypoglossal
nerve dysfunction is caused by OSA and/or is in
part responsible for OSA, or is an epiphenome-
non. Further research is necessary to understand
the relationship between hypoglossal nerve func-
tion and upper airway collapse. Future studies
could include hypoglossal NCS in OSA patients
who do not snore as well as longitudinal assess-
ment of newly diagnosed OSA patients with and
without treatment with CPAP.
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